European stocks rise; Genmab shares surge 7.7%
GMAB Genmab ADR
$38.48 +10.73%
View chart & analysis → - 1Genmab shares rose 7.7%, hitting a three-year high.
- 2The combination therapy from AbbVie and Genmab reduced the risk of disease progression or death in newly diagnosed lymphoma patients.
- 3The STOXX 600 index rose 0.8% to 638.67 points.
So what's the key point?
Genmab shares rose 7.7% following news that its treatment reduced risks for cancer patients. The stock jumped significantly as the effectiveness of the treatment was demonstrated.
Source Reuters · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.